Lp(a): the inherited risk marker most people are never tested for

Largely genetic, mostly unaffected by diet and statins, and worth measuring once. What an elevated Lp(a) does and does not mean.

Key takeaways

  • Lp(a) is an LDL-like particle carrying an extra protein, apolipoprotein(a). Your concentration is largely inherited.
  • Because it is genetically set, it stays broadly stable through adult life, which is why consensus guidance suggests measuring it at least once.
  • Diet, exercise and statins do not meaningfully lower it. Statins may raise it modestly.
  • Elevated Lp(a) is associated with atherosclerotic cardiovascular disease and with aortic valve stenosis, supported by Mendelian randomization evidence.
  • An elevated result does not change into a diagnosis. It changes how aggressively everything else you can modify gets managed.

Lipoprotein(a) is an LDL-like particle carrying an extra protein called apolipoprotein(a). Your level is largely set by genetics.

Because it barely responds to diet, exercise or statin therapy, it is a marker you measure to understand your risk baseline rather than one you chase down.

European consensus guidance recommends measuring it at least once in adult life. Most people never have.

What Lp(a) is

Lipoprotein(a) is an LDL particle with an additional protein, apolipoprotein(a), attached. That protein is structurally similar to plasminogen, which is part of why Lp(a) is thought to contribute through both atherogenic and pro-thrombotic routes.

The important feature is genetic. Concentration is largely determined by variation in the LPA gene, including the number of repeats in the apo(a) isoform, and levels differ substantially by ancestry. It is not something you developed through lifestyle.

Why once is usually enough

Because the level is inherited and stays broadly stable across adult life, repeat testing rarely adds information. The 2022 EAS consensus statement recommends measuring Lp(a) at least once in every adult.

One measurement detail worth knowing: Lp(a) can be reported in mg/dL or in nmol/L, and the two are not interchangeable by a simple conversion because particle size varies. Commonly cited risk thresholds are around 50 mg/dL or roughly 125 nmol/L. Compare like units, and preferably like laboratories.

What an elevated result means

Large genetic studies, including Mendelian randomization analyses, support Lp(a) as a causal contributor to atherosclerotic cardiovascular disease rather than an incidental marker. It is also associated with calcific aortic valve stenosis.

What it is not is a verdict. Roughly one in ten to one in five people has an elevated Lp(a), and plenty of them will never have an event. Absolute risk depends on everything else: ApoB, blood pressure, glucose handling, smoking, family history.

That is the practical consequence of the test. You cannot lower Lp(a) with the tools currently available to most people, so an elevated value shifts attention to the levers that do move, and it makes the case for taking them seriously earlier. It is also a reason to raise family screening, since first-degree relatives may share it.

What does and does not lower it

Being straightforward about this saves people a lot of wasted effort.

  • Diet, exercise and weight loss: no meaningful effect on Lp(a) itself. They still change your overall risk, which is the point.
  • Statins: do not lower Lp(a), and may raise it slightly. They remain indicated on their own merits for ApoB and LDL-C.
  • PCSK9 inhibitors: lower it modestly, though Lp(a) reduction is not their primary indication.
  • Lipoprotein apheresis: used in specific severe cases, in specialist settings.
  • Targeted therapies designed to lower Lp(a) directly have reached late-stage outcome trials, and the first of them has now read out. In September 2026 Novartis reported that Lp(a)HORIZON, the phase 3 cardiovascular outcomes trial of pelacarsen, did not meet its primary endpoint despite substantial Lp(a) lowering. Amgen's olpasiran outcomes trial, OCEAN(a), is still running. So whether lowering Lp(a) reduces events remains unsettled, and the first answer we have is a negative one.

How Baseline uses it

We recommend measuring Lp(a) once if you opt into lab work, since one value is usually enough for life. An elevated result does not generate a peptide protocol, because that is not what it calls for. It changes the surrounding conversation: tighter attention on ApoB and blood pressure, earlier consideration of imaging with your physician, and a prompt to have close relatives tested.

Where it warrants specialist cardiology input, we say so. Knowing the limits of what a wellness practice should handle is part of handling it properly.

What this means for you

Have Lp(a) measured once. If it is elevated, the response is not to chase the number itself but to manage everything modifiable more assertively, and to tell your immediate family to get tested.

References

  1. Kronenberg et al., lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis, EAS consensus statement, European Heart Journal, 2022
  2. Clarke et al., genetic variants associated with Lp(a) lipoprotein level and coronary disease, New England Journal of Medicine, 2009
  3. Kamstrup et al., genetically elevated lipoprotein(a) and increased risk of myocardial infarction, JAMA, 2009
  4. Biomarker hub: Cardiovascular biomarkers

More in Biomarker hub